Drug Development

Soprano Eleonora Buratto lends her voice to fight 'butterfly disease,' highlighting an innovative venture philanthropy model rewriting the playbook for rare illnesses.

Acrivon's ACR-2316 shows durable responses in lung cancer, moving to the next phase. The trial's design, guided by AI, aligns with new FDA standards.

Bristol Myers Squibb's large-scale deployment of Schrödinger's Bunsen AI isn't just a software deal; it's a strategic signal for the future of pharma R&D.

As Ascentage Pharma preps its mid-year report, we look beyond the balance sheet at the strategic plays and clinical trials fueling its global oncology ambitions.

Expedition Therapeutics lands a huge Series B and starts a pivotal trial for a drug that could finally target the root cause of COPD for millions.

A quiet South Korean biotech is shaking up the drug delivery landscape. Alteogen's latest deal signals a major shift as Big Pharma races to make treatments better.

Eton Pharmaceuticals' new deal for ASN-001 is more than a pipeline buy; it's a calculated maneuver to capture the entire infantile hemangioma treatment space.

A revenue dip masks a calculated pivot. UTHR is betting its future not just on new drugs, but on a revolutionary plan to manufacture human organs.

Compass Pathways is racing towards a 2027 launch for its psilocybin therapy. But can it navigate the complex regulatory and commercial hurdles to deliver on its promise?

As Everest Medicines preps its H1 2026 results, investors are watching for more than just profit, focusing on its pivot to a global innovation engine.

Attovia Therapeutics’ successful IPO injects massive capital into its ambitious pipeline, but can its novel multi-specific antibody platform outmaneuver giants?

With a fortified balance sheet and a strategic pivot, OnKure Therapeutics is betting that precision and selectivity will conquer a competitive drug market.

A new partnership unites AI data-crunching with lab-grown human brain organoids, charting a bold roadmap to deconstruct Parkinson's into treatable subtypes.

Immix Biopharma heads to Morgan Stanley's key conference. Can its promising CAR-T therapy for AL Amyloidosis convince investors to fund the final mile?

Entropy Neurodynamics launches a world-first 'basket study' for its IV psilocin, a high-stakes bet that could redefine mental health treatment pipelines.

In a strategic play, Archeus Technologies overhauls its advisory board, positioning itself to accelerate its cancer therapy pipeline in the booming RPT market.

A new oral tablet from Entera Bio could replace painful daily injections for millions with severe osteoporosis, a move validated by a top scientific conference.

Healis Therapeutics gets FDA nod for Tyemvers, a botulinum toxin therapy for depression. Can a drug that paralyzes frown muscles disrupt mental healthcare?

After a corporate overhaul and a massive cash infusion, Faeth Therapeutics is pushing its multi-pronged cancer drug PIKTOR toward pivotal clinical data.

An award for a Virginia nurse is more than a headline. It's a signal of a strategic revolution in healthcare, where community clinics become global powerhouses.